Epilepsy, a chronic neurological disorder characterized by recurrent seizures, affects over 65 million people worldwide. The management of epilepsy has witnessed significant advancements in recent years. This article provides a comprehensive update on these developments for healthcare professionals.
Advancements in neuroimaging technologies such as high-resolution MRI and PET scans have enhanced the identification of structural and functional abnormalities in epilepsy. Genomic testing has also emerged as a valuable diagnostic tool, enabling personalized treatment strategies based on individual genetic profiles.
Over the past decade, several new AEDs have been introduced, offering improved safety and efficacy profiles. These include lacosamide, perampanel, and brivaracetam. Furthermore, the development of long-acting injectable AEDs has improved treatment adherence and quality of life for patients.
Neuromodulation therapies such as vagus nerve stimulation (VNS), responsive neurostimulation (RNS), and deep brain stimulation (DBS) have shown promising results in drug-resistant epilepsy. These therapies offer an alternative treatment approach for patients who are not suitable candidates for epilepsy surgery.
Minimally invasive surgical techniques such as laser interstitial thermal therapy (LITT) and stereotactic radiosurgery (SRS) have revolutionized epilepsy surgery. These techniques offer significantly reduced morbidity and improved postoperative outcomes compared to traditional surgical methods.
The landscape of epilepsy management is rapidly evolving, with advancements in diagnostic tools, AEDs, neuromodulation therapies, and surgical techniques. These developments are paving the way towards personalized, efficient, and less invasive treatment strategies, improving the quality of life for individuals living with epilepsy. It is crucial for healthcare professionals to stay updated on these advancements to provide optimal care for their patients.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation